RETRACTION

Open Access Full Text Article

## MicroRNA-139-3p Inhibits the Growth and Metastasis of Ovarian Cancer by Inhibiting ELAVLI [Retraction]

Xue F, Li QR, Xu YH, Zhou HB. Onco Targets Ther. 2019;12:8935-8945.

At the authors request, the Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. The authors notified the journal that the primers meant for miR-139-3p had mistakenly been designed for miR-129-3p and the conclusions described in the reported study were unreliable. In addition, it was also found that images in Figure 3 had been duplicated. Specifically,

• Figure 3A, OVCAR-3, 0 h, miR-NC appears to have been duplicated with the same image for Figure 3A, OVCAR-3, 0 h, miR-139-3p.

The authors were unable to explain how the incorrect primers came to be designed or how the images in Figure 3A came be to be duplicated. The authors were also unable to provide the original data for their study. The Editor agreed with the authors request to retract the article.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

## **OncoTargets and Therapy**

Dovepress

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.\$384255

Received: 29 July 2022 Accepted: 29 July 2022 Published: 2 August 2022

## OncoTargets and Therapy 2022:15 839

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com terms.php and incorporate the Greative Commons Attribution — Non Commercial (unported, v3.0). License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

839